Taken together, these findings indicate that XOR inhibitor treatment might exert protective effects on sarcopenia in HD patients through preservation of skeletal muscle mass and improvement of skeletal muscle function by ATP enhancement in skeletal muscle. This evidence concerns the gene XDH and sarcopenia.